Lotus Pharmaceutical Announces First Hospital Formulary Listing and Commercial Shipment for Bostini® (bosutinib) in Taiwan Following TFDA Approval

Taipei, Taiwan, 15 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced the first hospital formulary listing and initial commercial shipment of Bostini® (bosutinib) in Taiwan, marking an important milestone following the product's approval by the Taiwan Food and Drug Administration (TFDA) in 20251. The achievement represents the successful transition from regulatory approval to hospital adoption, demonstrating Lotus' strong commercial execution and its ability to efficiently expand access to important oncology treatments for patients in Taiwan.

Bostini® (bosutinib), Lotus’ in-house-developed generic version of Bosulif®, is a second-generation tyrosine kinase inhibitor (TKI) indicated for adult patients with newly diagnosed chronic-phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML), as well as those with resistance or intolerance to prior TKI therapies. According to IQVIA, the market of TKIs used in the treatment of CML in Taiwan was valued at approximately US$66 million in 20252.

The availability of Bostini® marks an important step in expanding treatment options for patients with CML in Taiwan, providing physicians with greater flexibility to tailor treatment according to individual patient characteristics, including where cardiovascular risk profile is an important treatment consideration.

Petar Vazharov, Chief Executive Officer of Lotus, commented: “Bostini® is an important milestone for Lotus, reflecting our integrated capabilities across research and development, regulatory execution and commercialisation. Achieving hospital formulary listing and initial commercial shipment in just over a year after TFDA approval through Taiwan’s NCE-2 pathway demonstrates the strength of our execution and the value of our Taiwan commercial platform. We remain committed to strengthening our oncology portfolio and expanding access to high-barrier, differentiated medicines for patients.”

Bosulif® is a registered trademark of its respective owner. Bostini® is a registered trademark of Lotus Pharmaceutical Co Ltd. All other trademarks are the property of their respective owners.

¹ https://www.lotuspharm.com/en/newsroom/news-page/25/bosutinib-tfda-approval

² 2025 IQVIA sales of asciminib, dasatinib, imatinib, nilotinib and ponatinib

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.